Anticoagulation in Patients With Cancer Authors: Gregory Piazza Published: 2024 ABSTRACT Video InsightsKey Words: anticoagulation, atrial fibrillation, cancer, venous thromboembolism Because atrial fibrillation (AF) and pulmonary embolism are increasingly recognized as comorbid conditions and complications in patients with active cancer, the need for safe and effective pathways for anticoagulation in this vulnerable population is rapidly growing. Mechanisms for AF arrhythmogenesis in patients with cancer include increased production of proinflammatory cytokines, development of incident cardiovascular disease such as atherosclerosis and cardiomyopathy, and toxicities related to cancer-directed therapy such as Bruton tyrosine kinase inhibitors.1,2 Venous thromboembolism (VTE), including pulmonary embolism, is a growing source of morbidity and mortality in patients with cancer and is related to platelet activation, upregulation of tissue factor expression, increased levels of circulating microparticles, and circulating proinflammatory cytokines.3,4 Patients with cancer and AF frequently present a challenge for safe and effective anticoagulation because of simultaneously increased risk of stroke and major bleeding.5 Greater integration of direct oral anticoagulant (DOAC) utilization for stroke prevention in AF over the past decade has provided clinicians and patients with a safe and effective and more convenient alternative to vitamin K antagonists in patients with cancer.3,6 Likewise, DOACs have emerged as an often-preferred alternative to low-molecular weight heparins for anticoagulation in patients with cancer with VTE.3 However, an ongoing obstacle to optimal anticoagulation strategies with DOACs is the concern of drug–drug interactions between these anticoagulants and cancer-directed therapies, including those used in investigational protocols. In the case of this clinical vignette, ibrutinib used for the treatment of chronic lymphocytic leukemia may potentiate the risk of major bleeding on anticoagulation due to its inhibition of platelet aggregation via the glycoprotein VI pathway.7 Stepwise strategies for safe management of AF in patient with cancer (eg, the Atrial Fibrillation Better Care pathway) facilitate the assessment of stroke and bleeding risks and encourage mitigation of factors that further complicate stroke prevention and arrhythmia control.8 Furthermore, understanding the risk of drug–drug interactions among all options plays an integral role in anticoagulant selection. In a population-based cohort study, warfarin demonstrated a greater risk of bleeding (HR: 7.33; 95% CI: 2.11-25.48) in patients receiving concomitant ibrutinib than those prescribed DOACs (HR: 1.91; 95% CI: 0.79-4.64).9 The oncology team planned to continue ibrutinib because the patient had been responding well. However, the team expressed concern about the use of a DOAC with ibrutinib and risk of bleeding. The patient was discharged on weight-based enoxaparin and found self-injection challenging. The patient was referred to cardiovascular medicine for consideration of options for long-term anticoagulation. After a shared decision-making discussion with the patient and the oncology team, the cardiovascular medicine consultant recommended transition from enoxaparin to apixaban 5 mg twice daily. Ibrutinib was continued with careful monitoring. In routine follow-up, he had not had any return of AF, recurrent VTE, or bleeding complications. The following is the video related to this paper. Funding Support and Author Disclosures Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, BSC, and Esperion (1R01HL164717-01); and has an advisory role for BSC, Amgen, BCRI, PERC, NAMSA, BMS, Janssen, and Regeneron. Footnotes This paper was part of a supplement sponsored by Pfizer. The sponsor had no influence or involvement over the review or approval of any content. Geoffrey Barnes, MD, served as the Guest Editor-in-Chief for this content. The author attests they are in compliance with human studies committees and animal welfare regulations of the author’s institution and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References Associated Data Supplementary Materials